Literature DB >> 19558503

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

F Sellebjerg1, M Krakauer, D Hesse, L P Ryder, I Alsing, P E H Jensen, N Koch-Henriksen, A Svejgaard, P Soelberg Sørensen.   

Abstract

OBJECTIVE: Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.
METHODS: Gene expression was studied on DNA arrays in untreated patients, in NAb negative patients, and in MS patients with varying NAb levels 9-12 h and 36-48 h after IFN-beta administration. The expression of selected genes was measured by real-time PCR. NAb levels were assessed by a cytopathic effect assay.
RESULTS: Several hundred genes were induced 9-12 h after an injection of IFN-beta. The molecules CXCL10, CCL2 and IFI27 were among the most strongly induced. Gene induction was generally much less pronounced after 36-48 h, but IFI27 remained strongly induced. The strong induction of these molecules and MxA was confirmed by real-time PCR. Induction of MxA, CCL2, CXCL10 and IFI27 was reduced in patients with low NAb levels and lost in patients with intermediate/high NAb levels.
CONCLUSION: We identify IFI27, CCL2 and CXCL10 as sensitive biomarkers for the response to IFN-beta. The expression of these markers adequately reflects bioactivity of IFN-ss as documented by the decreased induction in low NAb-positive patients and the lost induction in patients with moderate/high NAb levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558503     DOI: 10.1111/j.1468-1331.2009.02716.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  17 in total

Review 1.  The genetics of multiple sclerosis: an up-to-date review.

Authors:  Pierre-Antoine Gourraud; Hanne F Harbo; Stephen L Hauser; Sergio E Baranzini
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

Review 3.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

Review 4.  Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Authors:  Per Soelberg Sorensen
Journal:  CNS Drugs       Date:  2022-05-19       Impact factor: 6.497

5.  Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.

Authors:  Antonio Bertolotto; Marco Capobianco; Maria Pia Amato; Elisabetta Capello; Ruggero Capra; Diego Centonze; Maria Di Ioia; Antonio Gallo; Luigi Grimaldi; Luisa Imberti; Alessandra Lugaresi; Chiara Mancinelli; Maria Giovanna Marrosu; Lucia Moiola; Enrico Montanari; Silvia Romano; Luigina Musu; Damiano Paolicelli; Francesco Patti; Carlo Pozzilli; Silvia Rossi; Marco Salvetti; Gioachino Tedeschi; Maria Rosaria Tola; Maria Trojano; Maria Troiano; Mauro Zaffaroni; Simona Malucchi
Journal:  Neurol Sci       Date:  2013-12-29       Impact factor: 3.307

6.  Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.

Authors:  Tiina Kelkka; Deborah Kienhöfer; Markus Hoffmann; Marjo Linja; Kajsa Wing; Outi Sareila; Malin Hultqvist; Essi Laajala; Zhi Chen; Júlia Vasconcelos; Esmeralda Neves; Margarida Guedes; Laura Marques; Gerhard Krönke; Merja Helminen; Leena Kainulainen; Peter Olofsson; Sirpa Jalkanen; Riitta Lahesmaa; M Margarida Souto-Carneiro; Rikard Holmdahl
Journal:  Antioxid Redox Signal       Date:  2014-07-29       Impact factor: 8.401

7.  Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Authors:  Finn Sellebjerg; Martin Krakauer; Signe Limborg; Dan Hesse; Henrik Lund; Annika Langkilde; Helle Bach Søndergaard; Per Soelberg Sørensen
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

8.  Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.

Authors:  Alexander Hundeshagen; Michael Hecker; Brigitte Katrin Paap; Charlotte Angerstein; Ole Kandulski; Christian Fatum; Christiane Hartmann; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  J Neuroinflammation       Date:  2012-06-22       Impact factor: 8.322

9.  Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Authors:  Richard A Rudick; M R Sandhya Rani; Yaomin Xu; Jar-Chi Lee; Jie Na; Jennifer Shrock; Anupama Josyula; Elizabeth Fisher; Richard M Ransohoff
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

10.  Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.

Authors:  Sunny Malhotra; Marta F Bustamante; Francisco Pérez-Miralles; Jordi Rio; Mari Carmen Ruiz de Villa; Esteban Vegas; Lara Nonell; Florian Deisenhammer; Nicolás Fissolo; Ramil N Nurtdinov; Xavier Montalban; Manuel Comabella
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.